The effect of methotrexate on bone metabolism markers in patients with rheumatoid arthritis

References

• Sambrook PN. The skeleton in rheumatoid arthritis; common mechanisms for bone erosion and osteoporosis? J Ftheumatol 2002;27:2541–2.
   Google Scholar
• Joffe I, Epstein S. Osteoporosis associated with rheumatoid arthri-tis: pathogenesis and management. Semin Arthritis Rheum 1991;20:256–72.
   PubMed Web of Science ®Google Scholar
• Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthri-tis. Arthritis Rheum 1995;38:151–60.
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid ar-thritis: Annu Rev Med 2000;51:207–29.
   PubMed Web of Science ®Google Scholar
• Cranney AB, McKendry RJ, Wells GA, Ooi DS, Kanifsberg ND, Kraag GR, et al. The effect of low dose methotrexate on bone density. J Ftheumatol 2001;28:2395–9.
   Google Scholar
• El Miedany, Iman HL, Mohamed EL. Effect of low dose methotr-exate on markers of bone metabolism in patients with rheumatoid arthritis. J Ftheumatol 1998;25:2083–7.
   Google Scholar
• Garnero P, Delmas PD. New developments in biochemical markers for osteoporosis. Calcif Tissue Int 1996;59\(Suppl 1)82–9.
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries NS, Healey LA, et al. The American Rheumatism Association's 1987 revised criteria for the classification of rheumatoid arthritis. Ar-thritis Rheum 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Pincus T, Summary JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford health assessment questionnaire. Arthritis Rheum 1983;26:1346–53.
   Google Scholar
• Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Gold-smith C, et al. American Collage of Ftheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;6:727–35.
   Web of Science ®Google Scholar
• Gough AK, Peel NF, Eastell R, Holder RL, Lilley J, Emery P. excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis 1994;53:14–7.
   PubMed Web of Science ®Google Scholar
• Kollerup G, Hansen M, Horsley PK. Urinary hydroxyproline crosslinks of collagen in rheumatoid arthritis. Br J Ftheumatol 1994;33:816–20.
   Google Scholar
• Pereira RM, Corrente J, Chahade W, Cossermelli W. Levels of deoxypyridinoline cross-links in healthy children and children with juvenile rheumatoid arthritis (abstract). Arthritis Rheum 1996;7: 902–6.
   Google Scholar
• Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthri-tis. Arthritis Rheum 1995;38:151–60.
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid ar-thritis: Annu Rev Med 2000;51:207–29.
   PubMed Web of Science ®Google Scholar
• Azuma Y, Kaji K, Katori R, Takeshita S, Kudo A. Tumor necrosis factor- alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000;275:4858–64.
   Google Scholar
• Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y. Tumor necrosis factor-alpha (TNF) stimulates RANK signaling pathways. J Biol Chem 2001;276:563–8.
   Google Scholar
• Kobayashi K, Takahashi K, Jimi E. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/FtANKL-RANK interaction. J Exp Med 2000;191: 275–86.
   Google Scholar
• Jijmi E, Akiyama S, Tsurukai T. Osteodast differentiation factor acts as a multifunctional regulator in murine osteoclast differentia-tion and function. J Immunol 1999;163:434–42.
   Google Scholar
• Fuller K, Wong B, Fox S. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998;188:997–1001.
   Google Scholar
• Reid IR. Gulcocortocoid osteoporosis-mechanisms and manage-ment. Eur J Endocrinol 1997;137:209–17.
   PubMed Web of Science ®Google Scholar
• Lukert BP, Raisz LG. Glucocortocoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352–64.
   PubMed Web of Science ®Google Scholar
• Kim CH, Cheng SL, Kim GS. Effect of dexamethasone on prolif-eration, activity, and cytokine secretion of normal human bone marrow stromal cells: possible mechanisms of glucocorticoid-induced bone loss. J Endocrinol 1999;162:371–9.
   Google Scholar
• Dempster D. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 1998;13:137–41.
   Google Scholar
• Fujita T, Satomura A, Hidaka M, Ohsawa I, Endo M, Ohi H. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephritic patients receiving high-dose glu-cocorticoid and one cycle etidronate therapy. Calcif Tissue Int 2000;66:195–9.
   PubMed Web of Science ®Google Scholar
• Weinstein RS, Jilka RL, Parfit AM, Manolagas SC. Inhibition of osteodastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their del-eterious effects on bone. J Clin Invest 1998;102:274–82.
   PubMed Web of Science ®Google Scholar
• Gennari C, Imbimbo B, Montagnani M, Bermini M, Nardi P, Avioli LV. Effect of prednisone and deflazacort on mineral me-tabolism and parathyroid hormone activity in humans. Calcif Tis-sue Int 1984;36:245–52.
   PubMed Web of Science ®Google Scholar
• Dempster DW. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 1994;56:295–302.
   Google Scholar
• Lems WF, Gerrits MI, Jacobs JWG, van Vugt RM, van Rijn HJM, Bijlsma JWJ. Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheuma-toid arthritis. Ann Rheum Dis 1996;55:288–93.
   Google Scholar
• Yonemura K, Kimura M, Miyaji T, Hishida A. Short-term effect of vitamin K administration on prednisolone-induced loss of bone mineral density in patients with chronic glomerulonephritis. Calcif Tissue Int 2000;66:123–8.
   PubMed Web of Science ®Google Scholar
• Greenspan S, Rosen H, Parker R. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a random-ized clinical trial. J Bone Miner Res 1998;13:1431–8.
   Google Scholar
• Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Bone 1999;24:237–44.
   Google Scholar
• St Clair EW, Moak SA, Wilkinson. WE, Sanders L, Lang T, Greenwald RA. A cross sectional analysis of 5 different markers f collagen degradation in rheumatoid arthritis. J Ftheumatol 1998;25: 1472–9.
   Google Scholar
• Hall GM, Spector TD, Delmas PD. markers of bone metabolism in postmenopausal women with rheumatoid arthritis: effects of cord-costeroids and hormone replacement therapy. Arthritis Rheum 1995;38:902–6.
   Google Scholar